A detailed history of Nicholas Company, Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Nicholas Company, Inc. holds 169,745 shares of PCRX stock, worth $2.7 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
169,745
Previous 154,330 9.99%
Holding current value
$2.7 Million
Previous $4.51 Million 7.7%
% of portfolio
0.08%
Previous 0.08%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$25.5 - $31.51 $393,082 - $485,726
15,415 Added 9.99%
169,745 $4.86 Million
Q2 2023

Feb 13, 2024

SELL
$36.12 - $47.5 $2,528 - $3,325
-70 Reduced 0.05%
154,330 $6.18 Million
Q2 2023

Aug 08, 2023

SELL
$36.12 - $47.5 $2,528 - $3,325
-70 Reduced 0.05%
154,330 $6.18 Million
Q1 2023

Feb 13, 2024

BUY
$35.53 - $43.38 $415,345 - $507,112
11,690 Added 8.19%
154,400 $6.3 Million
Q1 2023

May 11, 2023

BUY
$35.53 - $43.38 $415,345 - $507,112
11,690 Added 8.19%
154,400 $6.3 Million
Q2 2022

Feb 13, 2024

BUY
$51.49 - $81.64 $10,555 - $16,736
205 Added 0.14%
142,710 $8.32 Million
Q2 2022

Jul 26, 2022

BUY
$51.49 - $81.64 $10,555 - $16,736
205 Added 0.14%
142,710 $8.32 Million
Q1 2022

Feb 13, 2024

SELL
$60.03 - $76.49 $709,854 - $904,494
-11,825 Reduced 7.66%
142,505 $10.9 Million
Q4 2021

Feb 11, 2022

BUY
$47.97 - $62.21 $822,925 - $1.07 Million
17,155 Added 13.69%
142,505 $8.58 Million
Q3 2021

Nov 15, 2021

BUY
$54.64 - $61.3 $547,219 - $613,919
10,015 Added 8.68%
125,350 $7.02 Million
Q2 2021

Aug 12, 2021

BUY
$59.18 - $69.99 $526,406 - $622,561
8,895 Added 8.36%
115,335 $7 Million
Q1 2021

May 14, 2021

SELL
$59.31 - $78.82 $2,965 - $3,940
-50 Reduced 0.05%
106,440 $7.46 Million
Q4 2020

Feb 10, 2021

BUY
$50.47 - $66.26 $5.37 Million - $7.06 Million
106,490 New
106,490 $6.37 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $728M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Nicholas Company, Inc. Portfolio

Follow Nicholas Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nicholas Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nicholas Company, Inc. with notifications on news.